Presentation + Paper
4 March 2019 Zebrafish xenograft breast cancer models for high-throughput drug response screening
Author Affiliations +
Abstract
The heterogeneity and dynamic nature of cancerous tumors, such as those seen in breast cancer, pose a unique challenge in determining treatment regimens. The use of zebrafish as an in vivo model of breast cancer provides a high-throughput model with the potential to screen for efficacious drugs on a patient-by-patient basis. In this study, we use two-photon microscopy to measure metabolic changes in zebrafish with xenografted breast cancer tumors before, during, and after treatment with the anti-cancer drug paclitaxel. We use this metabolic imaging data to evaluate the zebrafish as a robust in vivo model of breast cancer. Preliminary results suggest the xenograft tumors respond to treatment with paclitaxel at 48 hours post treatment, as demonstrated by significant changes in NAD(P)H fluorescence lifetimes.
Conference Presentation
© (2019) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Rebecca Schmitz, Alex J. Walsh, Kelsey Tweed, Steve Trier, Anna Huttenlocher, and Melissa C. Skala "Zebrafish xenograft breast cancer models for high-throughput drug response screening", Proc. SPIE 10888, Biophysics, Biology and Biophotonics IV: the Crossroads, 1088804 (4 March 2019); https://doi.org/10.1117/12.2513688
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Tumors

Breast cancer

Tumor growth modeling

Luminescence

Cancer

In vivo imaging

Fluorescence lifetime imaging

Back to Top